

Special Issue

Acute Myeloid Leukemia: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editors

This Special Issue, entitled "Acute Myeloid Leukemia: From Pathophysiology to Novel Therapeutic Approaches", will mainly focus on understanding the factors that drive tumor progression and will assess the introduction of selective pathway inhibitors that tackle AML progression. The outcome for patients with AML is improving as a result of combined efforts in academic and industrial research that introduced several new therapies, some of which are specifically addressed toward the inhibition of pathways involved in leukemogenesis. We invite authors to submit original research and review articles that focus on the pathophysiology and new therapeutic strategies for AML. Potential topics include, but are not limited to:

- Molecular pathogenesis of AML
- Prognostic stratification
- The role of MRD
- New agents for AML
- New immunotherapeutic approaches
- The current role of allogeneic stem cell transplantation

Guest Editors

Prof. Dr. Rotraud Wieser

Dr. Giorgia Simonetti

Dr. Felicetto Ferrara

Deadline for manuscript submissions

closed (30 November 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/42371

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).